Litigation Details for Bayer Schering Pharma AG v. Lupin Ltd (D. Nev. 2010)

Bayer Schering Pharma AG v. Lupin Ltd (D. Nev. 2010)

Docket	2:10-cv-01166	Date Filed	2010-07-15
Court	District Court, D. Nevada	Date Terminated	2013-11-27
Cause	35:271 Patent Infringement	Assigned To	Kent J. Dawson
Jury Demand	Plaintiff	Referred To	Robert J Johnston
Parties	LUPIN PHARMACEUTICALS INC.
Patents	6,787,531; 6,958,326; 7,163,931
Attorneys	Robert F. Green
Link to Docket	External link to docket

Details for Bayer Schering Pharma AG v. Lupin Ltd (D. Nev. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-07-15				External link to document

Bayer Schering Pharma AG v. Lupin Ltd. Litigation Summary and Patent Analysis, 2:10-cv-01166

Last updated: August 31, 2026

Bayer Schering Pharma AG v. Lupin Ltd., No. 2:10-cv-01166, was an ANDA patent case in the U.S. District Court for the District of New Jersey involving Lupin’s proposed generic version of Bayer’s Yasmin oral contraceptive. The asserted patent was U.S. Patent No. 6,787,531, covering pharmaceutical compositions containing drospirenone and ethinyl estradiol. The Federal Circuit affirmed Bayer’s position in a 2012 decision, rejecting Lupin’s invalidity challenge. Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316 (Fed. Cir. 2012).

The dispute was part of Bayer’s broader Yaz/Yasmin patent enforcement program. The case concerned formulation and composition claims, not biologic interchangeability or biosimilar substitution. The patent’s commercial significance was tied to the U.S. market for combined oral contraceptives containing drospirenone.

What drug and patent were involved in Bayer v. Lupin?

The case involved Yasmin, Bayer’s branded combined oral contraceptive containing:

Product element	Yasmin specification
Progestin	Drospirenone
Estrogen	Ethinyl estradiol
Typical strength	3 mg drospirenone and 0.03 mg ethinyl estradiol
Dosage form	Oral tablet
Regulatory pathway	Lupin ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act
Branded manufacturer	Bayer Schering Pharma AG and related Bayer entities
Generic applicant	Lupin Ltd.
Primary patent	U.S. Patent No. 6,787,531
Litigation number	2:10-cv-01166, District of New Jersey

The ’531 patent claimed pharmaceutical compositions using drospirenone in combination with ethinyl estradiol. The patent also addressed the physical form and pharmaceutical presentation of drospirenone, including micronized material. Those limitations mattered because drospirenone has formulation and dissolution characteristics that affect oral absorption.

Lupin’s ANDA filing was treated as a Paragraph IV certification, meaning Lupin asserted that the relevant patent was invalid, unenforceable, or would not be infringed by its proposed generic product. Bayer responded by filing an infringement action under 35 U.S.C. § 271(e)(2), which triggered the statutory 30-month stay of FDA approval.

What was the litigation timeline in Bayer Schering Pharma AG v. Lupin?

The key procedural events were:

Date	Event
March 10, 2010	Bayer filed the action in the District of New Jersey under No. 2:10-cv-01166
2010-2011	The parties litigated infringement, claim construction, and validity issues involving the ’531 patent
2011-2012	The district court proceedings produced the judgment appealed by Lupin
April 2012	The Federal Circuit issued its decision at 676 F.3d 1316
March 17, 2020	The ’531 patent’s ordinary patent term expired, subject to any applicable statutory adjustment or extension

The case was decided within the first wave of generic challenges involving Bayer’s drospirenone contraceptive products. Bayer had also litigated related patent issues against other ANDA sponsors, including Barr Laboratories. The Federal Circuit’s earlier decision in Bayer Schering Pharma AG v. Barr Laboratories, Inc., 575 F.3d 1341 (Fed. Cir. 2009), addressed the same commercial patent family and helped define the legal framework for later challenges.

What did the Federal Circuit decide in Bayer v. Lupin?

The Federal Circuit affirmed the district court’s judgment in Bayer’s favor. The appellate decision addressed Lupin’s challenges to the asserted claims, including claim construction and obviousness issues associated with the claimed drospirenone and ethinyl estradiol composition.

The ruling preserved the enforceability of Bayer’s patent against Lupin’s ANDA product. The decision did not create a general rule that all drospirenone contraceptive products were covered by the ’531 patent. Instead, the outcome depended on the particular claim language, the ANDA product, the cited prior art, and the evidence presented in the case.

The central analytical points were:

1. The claimed pharmaceutical composition was evaluated as a combination of active ingredients and formulation limitations.
2. Lupin was required to establish invalidity under the applicable clear-and-convincing-evidence standard.
3. The prior art did not make the claimed combination obvious on the record before the court.
4. The patent’s formulation-related limitations had legal significance beyond the identity of the two active ingredients.
5. The appellate court left the judgment favorable to Bayer in place.

The Federal Circuit’s ruling therefore maintained Bayer’s ability to use the ’531 patent as an obstacle to Lupin’s commercial launch during the remaining patent term.

How did the patent claims affect the outcome?

The ’531 patent was important because it did not merely identify drospirenone as a contraceptive active ingredient. The claims were directed to a specific pharmaceutical composition involving drospirenone, ethinyl estradiol, and formulation characteristics relevant to oral administration.

Formulation protection

The patent’s formulation protection included limitations concerning micronized drospirenone. Micronization reduces particle size and can improve dissolution and absorption. In pharmaceutical patent litigation, such limitations can distinguish a claimed product from earlier disclosures of the same active ingredient.

A generic applicant may avoid infringement by changing the particle-size profile, excipient system, dosage strength, or other formulation parameter. That strategy depends on the precise claim language and the product characteristics disclosed in the ANDA. In this case, the court’s treatment of the formulation limitations favored Bayer.

Composition protection

The patent also protected the combination of drospirenone and ethinyl estradiol in the claimed oral contraceptive arrangement. The existence of earlier references discussing either component separately did not automatically establish obviousness of the claimed product.

Method-of-use protection

The reported appellate decision focused primarily on composition and formulation issues. The case was not principally a dispute over a narrow method-of-use patent for a new indication. The commercial use was contraception, but the litigation’s patent value came from the product claims covering the active-ingredient combination and formulation.

What was Lupin’s Paragraph IV challenge?

Lupin’s ANDA challenge placed the patent at risk under the Hatch-Waxman framework. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. Once Bayer sued within the statutory period, FDA approval of Lupin’s ANDA was generally stayed for up to 30 months unless the litigation ended earlier or the court modified the stay.

Lupin’s position required it to prevail on one of the principal defenses:

• The patent claims were invalid for anticipation.
• The claims were invalid for obviousness.
• Lupin’s proposed product did not infringe.
• The patent was unenforceable.

The Federal Circuit decision left Lupin without a judicial victory on those issues. The ruling did not, however, prevent all future generic competition. Once the patent term expired, later ANDA applicants could pursue approval subject to any other applicable patents, regulatory exclusivity, or settlement restrictions.

What was the Orange Book status of Yasmin?

The ’531 patent was associated with Bayer’s Yasmin product and was relevant to the FDA Orange Book patent-listing system. Orange Book listings provide notice of patents that a brand sponsor asserts cover an approved drug, its formulation, or an approved method of use.

The Orange Book framework mattered for three reasons:

1. It enabled Bayer to list the patent against the approved product.
2. It allowed Lupin to make a Paragraph IV certification.
3. It triggered statutory litigation consequences when Bayer filed suit.

Orange Book listing did not itself establish validity or infringement. Those issues were determined in the district court and on appeal. The Federal Circuit’s decision supplied the operative judicial determination for the Bayer-Lupin dispute.

The patent’s ordinary term ended in 2020, substantially after the 2012 Federal Circuit ruling. The commercial impact of the judgment therefore extended beyond the date of the appellate decision.

When did Bayer lose exclusivity for the ’531 patent?

The ’531 patent’s ordinary expiration date was March 17, 2020. The date is derived from the patent’s term and is consistent with public patent records for U.S. Patent No. 6,787,531.

Exclusivity component	Status
Patent protection	Expired in March 2020
FDA small-molecule exclusivity	Not a biologic exclusivity issue
Biosimilar exclusivity	Not applicable
Hatch-Waxman litigation stay	Operated during the ANDA dispute, subject to statutory rules
Post-expiration risk	Depended on other listed patents, regulatory barriers, and commercial factors

Patent expiration did not guarantee immediate generic market entry. A generic applicant could still face other patents, manufacturing claims, pediatric exclusivity, regulatory deficiencies, supply constraints, or commercial settlement terms. The ’531 patent itself, however, ceased to provide an ordinary blocking right after expiration.

Did this case involve biosimilar risk?

No. The case involved a conventional small-molecule drug and an ANDA, not a biologic license application or a biosimilar application under the Public Health Service Act.

The relevant competitive risks were:

• ANDA-based generic substitution.
• Paragraph IV invalidity and noninfringement challenges.
• Formulation design-around strategies.
• Patent-term expiration.
• Additional patents covering related drospirenone products.

Biosimilar concepts such as interchangeability, the Biologics Price Competition and Innovation Act, and reference-product exclusivity were not material to the litigation.

Which companies challenged Bayer’s Yasmin patent estate?

Bayer faced multiple generic challenges to its drospirenone contraceptive franchise. Barr Laboratories was a prominent challenger in related litigation, and Lupin was another ANDA sponsor that pursued a patent challenge.

The earlier Barr litigation was significant because the Federal Circuit upheld Bayer’s position concerning the ’531 patent and rejected an obviousness attack. The Lupin appeal produced a later Federal Circuit decision that likewise favored Bayer. These cases reduced the likelihood that a challenger could invalidate the principal Yasmin composition patent before its scheduled expiration.

The competitive landscape included generic manufacturers pursuing products corresponding to Yasmin and related Bayer products, including Yaz. The distinction between Yasmin and Yaz was commercially important because the products had different ethinyl estradiol strengths and approved labeling, even though both used drospirenone as the progestin.

How strong was Bayer’s patent estate?

The ’531 patent was a strong litigation asset during its enforceable term for four reasons:

1. Federal Circuit validation

Bayer obtained favorable Federal Circuit decisions in both the Barr and Lupin disputes. Appellate treatment materially increased the litigation risk for later ANDA challengers relying on similar prior-art theories.

2. Product-specific formulation claims

Claims directed to micronized drospirenone and the claimed combination narrowed the room for a generic applicant to copy the commercial product without addressing formulation limitations.

3. Long remaining term after appeal

When the Lupin appeal was decided in 2012, the patent had several years remaining before its 2020 expiration. That gave Bayer meaningful leverage in settlement negotiations and launch-control discussions.

4. Regulatory linkage

The patent’s Orange Book status connected the patent dispute to FDA approval timing. That linkage increased the financial value of a successful infringement case even though the patent could not prevent products outside its claim scope.

The estate was not unlimited. Patent strength depended on the individual claims and did not necessarily cover every drospirenone contraceptive formulation. Generic manufacturers could pursue noninfringing formulations, challenge other patents separately, or enter after expiration.

What patent litigation affected generic launch timing?

The Bayer-Lupin case likely delayed or threatened Lupin’s launch while the litigation and statutory stay remained active. The precise commercial launch date depended on the final judgment, any appellate mandate, regulatory approval, and any private settlement terms.

A launch before patent expiration could expose Lupin to:

• Injunctive relief.
• Damages or an account of profits.
• Willfulness allegations in appropriate circumstances.
• Regulatory and commercial disruption.
• Loss of first-filer or other ANDA-related advantages.

A launch after patent expiration would remove the ’531 patent as a direct barrier, but it would not resolve separate patent or regulatory issues involving other Bayer products or formulations.

Were there settlement agreements in the case?

The public appellate decision establishes the litigation outcome but does not, by itself, establish the existence or terms of a confidential commercial settlement. Hatch-Waxman cases often resolve through licensing or agreed-entry arrangements, but the reported decision should not be treated as evidence of a specific Lupin-Bayer settlement unless a filed agreement or regulatory disclosure confirms it.

No reliable conclusion about a licensed launch date, payment terms, authorized generic arrangement, or supply agreement follows solely from the docket number and appellate opinion.

What was the commercial exposure for Bayer?

Yasmin was part of Bayer’s broader women’s-health franchise, which also included Yaz and related drospirenone products. The ’531 patent protected an important product configuration during a period when generic substitution could materially reduce branded revenue.

The commercial exposure had three dimensions:

Exposure	Effect of an adverse ruling
Yasmin sales	Generic entry could reduce price and prescription volume
Related drospirenone franchise	A weak ruling could encourage challenges to related patents
Negotiating leverage	Invalidity or noninfringement could reduce Bayer’s ability to delay entry

The Federal Circuit result preserved Bayer’s legal leverage but did not guarantee continued sales after patent expiration. Oral contraceptive markets are sensitive to generic substitution, payer formulary decisions, pharmacy substitution rules, and price competition.

Key Takeaways

• Bayer Schering Pharma AG v. Lupin Ltd., No. 2:10-cv-01166, was a Hatch-Waxman ANDA dispute involving Yasmin.
• The principal patent was U.S. Patent No. 6,787,531.
• The patent covered a drospirenone and ethinyl estradiol pharmaceutical composition with formulation-related limitations, including micronized drospirenone.
• Lupin’s Paragraph IV challenge did not prevail.
• The Federal Circuit affirmed Bayer’s favorable result in 676 F.3d 1316 (Fed. Cir. 2012).
• The case involved a small-molecule generic, not a biosimilar.
• The ’531 patent expired in March 2020, ending its ordinary blocking effect.
• Bayer’s appellate success strengthened its negotiating position against generic applicants during the remaining patent term.
• The public decisions do not establish confidential settlement terms, a licensed launch date, or an authorized-generic arrangement.

FAQs

What was U.S. Patent No. 6,787,531 used to protect?

It protected pharmaceutical compositions containing drospirenone and ethinyl estradiol, including formulation limitations relevant to oral delivery and micronized drospirenone.

Was Bayer v. Lupin a patent infringement case or an FDA approval case?

It was a patent infringement action triggered by Lupin’s ANDA Paragraph IV certification. FDA approval timing was linked to the patent litigation through the Hatch-Waxman statutory stay.

Did the Bayer v. Lupin decision cover Yaz as well as Yasmin?

The litigation centered on Yasmin-related patent rights. Related drospirenone products such as Yaz could implicate overlapping or separate patents, but the case outcome should not be read as a blanket ruling covering every Bayer drospirenone product.

Could Lupin launch a drospirenone generic after the ’531 patent expired?

Expiration removed the ’531 patent as a blocking right. Launch still depended on FDA approval, other patents, regulatory requirements, and any applicable contractual or settlement restrictions.

What is the precedential value of 676 F.3d 1316?

The decision is relevant to claim construction, formulation limitations, and obviousness analysis for pharmaceutical composition patents. Its holding remains tied to the specific claims, prior art, evidence, and ANDA product litigated in the case.

References

1. Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316 (Fed. Cir. 2012).

2. Bayer Schering Pharma AG v. Barr Laboratories, Inc., 575 F.3d 1341 (Fed. Cir. 2009).

3. U.S. Patent No. 6,787,531. (2004). United States Patent and Trademark Office.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355.